PTC Therapeutics Announces CEO, Dr. Stuart Peltz Recipient of The New Jersey Technology Council's 2014 Legend of Technology Award
SOUTH PLAINFIELD, N.J., Nov. 21, 2014 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) is proud to announce that the 2014 Legend of Technology Award for Vision, Innovation, and Leadership has been awarded to Stuart W. Peltz, Ph.D., Chief Executive Officer. This award recognizes an individual who has had a significant impact on the technology industry in New Jersey for several decades.
"I am honored to receive the 2014 Legend of Technology Award," stated Stuart Peltz, Ph.D., CEO of PTC Therapeutics, Inc. "When I founded PTC over 16 years ago, my goal was to bring novel therapies to patients with little to no treatment options. Today, I'm excited to say that PTC is commercializing its first product to treat the underlying cause of nonsense mutation Duchenne muscular dystrophy. I am proud that we have been able to translate the innovative science developed in New Jersey into treatments for patients with little or no treatment options."
The 2014 New Jersey TechCouncil (NJTC) Awards Celebration honors the region's top technology companies and their leaders for their business accomplishments in technological collaboration, partnership and innovation. Each year the Tech Council selects an elite group to receive these awards. The awards were presented at the annual dinner celebration on November 20, 2014.
According to James Barrood, President and CEO of the Council, "We are thrilled to have so many outstanding companies and innovators to accept these awards. This year was particularly difficult to select those being honored from the many nominations we received. The judges were truly challenged and did a terrific job in identifying honorees that represent the best of the region's tech community."
About The New Jersey Technology Council:
The mission of the NJ Tech Council is to provide recognition, networking, education and services for the state and region's community. By collectively representing technology and tech related companies and organizations and service companies that support them, the Tech Council has the unique ability to:
- Offer opportunities to network and collaborate;
- Provide access to financing sources;
- Recognize and promote technological innovation and accomplishment;
- Offer educational resources and professional development opportunities; and
- Advocate for the tech, innovation and entrepreneurial communities.
Founded in 1996, NJ Tech Council has supported and nurtured the tech ecosystem across the state and region. For more information visit: www.njtc.org
About PTC Therapeutics, Inc.
PTC is a biopharmaceutical company focused on the discovery and development of orally administered, proprietary small molecule drugs that target post-transcriptional control processes. Post-transcriptional control processes regulate the rate and timing of protein production and are essential to proper cellular function. PTC's internally discovered pipeline addresses multiple therapeutic areas, including rare disorders, oncology and infectious diseases. PTC has developed proprietary technologies that it applies in its drug discovery activities and in collaborations with leading biopharmaceutical companies. PTC has received conditional marketing authorization in the European Economic Area for Translarna for the treatment of nonsense mutation Duchenne muscular dystrophy in ambulatory patients aged five years and older. Translarna is an investigational new drug in the United States. For more information on the company, please visit our website www.ptcbio.com
Forward Looking Statements:
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. All statements, other than those of historical fact, contained in this release, including statements regarding the future expectations, plans and prospects for PTC, our product and product candidates, our commercialization plans with respect to Translarna for the treatment of nonsense mutation Duchenne muscular dystrophy, and the potential advantages of Translarna are forward-looking statements. Our actual results, performance or achievements could differ materially from those expressed or implied by forward-looking statements we make as a result of a variety of risks and uncertainties, including those related to the initiation and conduct of clinical trials, availability of data from clinical trials, expectations for regulatory approvals, our scientific approach and general development progress, and the factors discussed in the "Risk Factors" section of our most recent Quarterly Report on Form 10-Q as well as any updates to these risk factors filed from time to time in PTC's other filings with the Securities and Exchange Commission. You are urged to carefully consider all such factors. The forward-looking statements included in this press release represent PTC's views only as of the date of this press release and we do not undertake or plan to update or revise any such forward-looking statements to reflect actual results or changes in plans, prospects, assumptions, estimates or projections, or other circumstances occurring after the date of this release except as required by law.
SOURCE PTC Therapeutics, Inc.
Share this article